NEW YORK (GenomeWeb News) — PerkinElmer said today it has closed the acquisition of ViaCell, an umbilical cord blood preservation business, for around $300 million, or $7.25 a share.
 
ViaCell collects and stores stem cells from newborns’ umbilical cords that might be of medical use by the child or a relative. PerkinElmer expects the company’s flagship ViaCord technology to complement its current prenatal screening tools for the risk of chromosomal abnormalities.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.